Rahul Saikia

Rahul Saikia has a diverse work experience in the pharmaceutical and finance industries. Rahul is currently the Head of Mergers and Acquisitions, Strategic Alliances at Rising Pharmaceuticals, where they played a key role in bringing HIG Capital as strategic investors into the company. Rahul is responsible for driving M&A evaluation pursuits and overseeing strategic initiatives for optimizing plant project completion and manufacturing efficiencies.

In 2020, Rahul also worked as a Strategic Advisor for Grace Therapeutics and CRONUS PHARMA LLC, providing guidance in strategic decisions and business development.

Prior to that, they were the Chief Strategy Officer at FDC Limited from 2018 to 2020, where they successfully turned around the company's net income growth. Rahul led strategic transformations and revitalization of the India Domestic Branded Generics business, as well as improved plant operations to capitalize on short supply situations in the US Gx market. Rahul also played a role in various transactions, including the Aceto Chapter 11 and the sale of Rising Pharmaceuticals.

Before joining FDC Limited, Rahul worked at PwC as the Director of Corporate Finance & Investment Banking, where they served from 2015 to 2018. Rahul also founded their own Independent Corporate Finance Advisory firm from 2012 to 2015.

In the earlier years of their career, Rahul held positions at ENAM as the Vice President of Investment Banking, at SSKI as an Investment Banking Associate, at Pfizer as a Strategy & Business Development Associate, and at ANZ as an Investment Banking Analyst.

Rahul Saikia's education history includes obtaining a Chartered Accountant degree from ICAI in Accounting & Finance in 2003. Rahul attended Apeejay School for their high school education, and St Edmunds in Shillong for an unspecified degree. Rahul also pursued a Bachelor of Commerce degree with a focus on Accounting from SYMBIOSIS INTERNATIONAL UNIVERSITY.

In addition to their formal education, Rahul has obtained several certifications. Rahul completed the "HMX Fundamentals - Genetics, Biochemistry, Pharmacology, Physiology, Immunology" course from Harvard Medical School in August 2021. In May 2020, they obtained the certifications for "Intellectual Property in the Healthcare Industry," "Introduction to Intellectual Property," and "Trademark Law" from the University of Pennsylvania. In September 2019, Rahul completed the "Introduction to the Biology of Cancer" course from The Johns Hopkins University.